Skip to main content
. Author manuscript; available in PMC: 2012 Dec 13.
Published in final edited form as: Cancer Cell. 2011 Dec 1;20(6):701–714. doi: 10.1016/j.ccr.2011.11.002

Figure 4. Antibody therapy targeting VCAM-1 and integrin α4 inhibits bone metastasis.

Figure 4

(A) BLI curves of bone metastasis development by PD2D cells in nude mice with control IgG or anti-VCAM-1 (clone P3C4) treatment started from Day 10. Data represent mean ± SEM. N=6. *p < 0.05 by Mann-Whitney test. (B) Representative BLI of mice treated with IgG or anti-VCAM-1 antibodies. (C) BLI curves of bone metastasis progression by PD2D cells with control IgG or anti-VCAM-1 treatment started from Day 62. BLI signals were normalized to Day 62 to facilitate comparison. Data represent mean ± SEM. N=6. *p < 0.05 by Mann-Whitney test. (D) BLI curves of bone metastasis development by PD2D cells with control IgG or anti-α4 (clone PS/2) treatment started from Day 0 until Day 21. Data represent mean ± SEM. N=10. **p < 0.01 by Mann-Whitney test. (E) Representative BLI of mice treated with IgG or anti-α4. (F) X-radiography of PD2D-injected mice treated with anti-VCAM-1 (A) or anti-α4 (D) at the end of experiments. Arrows point to osteolytic lesions. See also Figure S3.